Transcend Capital Advisors LLC Sells 285 Shares of RxSight, Inc. (NASDAQ:RXST)

Transcend Capital Advisors LLC cut its holdings in shares of RxSight, Inc. (NASDAQ:RXST) by 1.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 16,835 shares of the company’s stock after selling 285 shares during the period. Transcend Capital Advisors LLC’s holdings in RxSight were worth $1,013,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Larson Financial Group LLC purchased a new position in RxSight in the first quarter valued at about $51,000. RiverPark Advisors LLC boosted its stake in RxSight by 361.4% in the first quarter. RiverPark Advisors LLC now owns 3,082 shares of the company’s stock valued at $159,000 after acquiring an additional 2,414 shares during the last quarter. Amalgamated Bank boosted its stake in RxSight by 7.7% in the fourth quarter. Amalgamated Bank now owns 4,148 shares of the company’s stock valued at $167,000 after acquiring an additional 298 shares during the last quarter. Clear Rock Advisors LLC purchased a new position in RxSight in the fourth quarter valued at about $172,000. Finally, Clarus Group Inc. purchased a new position in RxSight in the fourth quarter valued at about $202,000. 78.78% of the stock is owned by institutional investors.

Insider Buying and Selling at RxSight

In other RxSight news, Director Julie Andrews sold 15,625 shares of the firm’s stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $58.00, for a total transaction of $906,250.00. Following the completion of the sale, the director now directly owns 30,287 shares in the company, valued at approximately $1,756,646. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other RxSight news, CFO Shelley B. Thunen sold 10,000 shares of the firm’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $58.61, for a total transaction of $586,100.00. Following the completion of the sale, the chief financial officer now directly owns 13,938 shares in the company, valued at approximately $816,906.18. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Julie Andrews sold 15,625 shares of RxSight stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $58.00, for a total transaction of $906,250.00. Following the completion of the sale, the director now owns 30,287 shares of the company’s stock, valued at $1,756,646. The disclosure for this sale can be found here. 9.36% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of brokerages recently commented on RXST. Needham & Company LLC upped their price target on shares of RxSight from $64.00 to $75.00 and gave the company a “buy” rating in a research note on Tuesday, May 7th. Oppenheimer upped their price target on shares of RxSight from $61.00 to $72.00 and gave the company an “outperform” rating in a research note on Tuesday, May 7th. Stifel Nicolaus decreased their target price on shares of RxSight from $75.00 to $70.00 and set a “buy” rating on the stock in a report on Wednesday, July 10th. Wells Fargo & Company upped their target price on shares of RxSight from $61.00 to $68.00 and gave the stock an “overweight” rating in a report on Tuesday, May 7th. Finally, BTIG Research upped their target price on shares of RxSight from $72.00 to $73.00 and gave the stock a “buy” rating in a report on Monday, July 15th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $65.14.

RxSight Stock Down 0.9 %

Shares of NASDAQ:RXST traded down $0.37 on Monday, hitting $41.40. The company had a trading volume of 500,739 shares, compared to its average volume of 480,434. The firm’s 50-day simple moving average is $53.84 and its two-hundred day simple moving average is $53.47. The firm has a market capitalization of $1.53 billion, a price-to-earnings ratio of -31.25 and a beta of 1.19. RxSight, Inc. has a 1 year low of $20.66 and a 1 year high of $66.54.

RxSight (NASDAQ:RXST) last issued its quarterly earnings results on Monday, May 6th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.08). The business had revenue of $29.51 million during the quarter, compared to the consensus estimate of $27.56 million. RxSight had a negative return on equity of 27.68% and a negative net margin of 44.01%. The firm’s revenue was up 68.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.42) earnings per share. Equities research analysts anticipate that RxSight, Inc. will post -0.75 EPS for the current year.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.